StockNews.AI
NYXH
StockNews.AI
98 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. – NYXH

1. Pomerantz LLP is investigating potential securities fraud by Nyxoah officers. 2. Nyxoah's FDA application for the Genio device received an Approvable Letter. 3. Analysts predict a delay in Genio's launch due to FDA review process. 4. On March 26, 2025, NYXH shares fell 21.36% following the announcement. 5. Investors are encouraged to contact Pomerantz LLP regarding class action claims.

4m saved
Insight
Article

FAQ

Why Bearish?

The investigation into securities fraud adds uncertainty and could lead to further stock price declines, similar to past incidents in biotech where legal issues have materially affected stock performance.

How important is it?

The ongoing investigation can significantly impact investor sentiment and stock price, especially in a highly regulated industry like biotech.

Why Short Term?

The immediate focus on the investigation and price drop suggests short-term volatility in NYXH's stock.

Related Companies

NASDAQ: FDANASDAQ: TLMDNASDAQ: ZYME
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Nyxoah and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 25, 2025, Nyxoah issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter regarding the Company’s Pre-Market Approval (PMA) application for the Genio® system”, which “means that Nyxoah’s application for marketing the device in the United States substantially meets the requirements of the Federal Food, Drug and Cosmetic Act and the FDA’s PMA implementing regulations . . . , and the FDA will approve the application subject to satisfactory completion of a manufacturing facilities, methods and controls review.” Following Nyxoah’s announcement, analysts projected that Genio’s commercial launch would be delayed pending further review by the FDA. On this news, Nyxoah’s stock price fell $2.42 per share, or 21.36%, to close at $8.91 per share on March 26, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News